Krystal Biotech Inc
NASDAQ:KRYS

Watchlist Manager
Krystal Biotech Inc Logo
Krystal Biotech Inc
NASDAQ:KRYS
Watchlist
Price: 190.4 USD 4.45% Market Closed
Market Cap: 5.5B USD
Have any thoughts about
Krystal Biotech Inc?
Write Note

Krystal Biotech Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Krystal Biotech Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Krystal Biotech Inc
NASDAQ:KRYS
Revenue
$241.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Revenue
$55.5B
CAGR 3-Years
0%
CAGR 5-Years
11%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$28.3B
CAGR 3-Years
1%
CAGR 5-Years
5%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Revenue
$32.5B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$10.6B
CAGR 3-Years
14%
CAGR 5-Years
24%
CAGR 10-Years
30%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$13.8B
CAGR 3-Years
1%
CAGR 5-Years
16%
CAGR 10-Years
18%
No Stocks Found

Krystal Biotech Inc
Glance View

Market Cap
5.5B USD
Industry
Biotechnology

Krystal Biotech, Inc. is a clinical-stage biotechnology company, which focuses on the development of redosable gene therapies to improve the lives of patients living with rare diseases. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 119 full-time employees. The company went IPO on 2017-09-20. Using its platform that is based on engineered herpes simplex virus type 1 (HSV-1), the Company create vectors that deliver therapeutic transgenes to cells of interest in multiple organ systems. The Company’s gene therapy product candidates and undertaking preclinical studies and clinical trials of B-VEC, KB105, KB301, KB104, KB407 and KB408. The firm's KB104 is to treat Netherton Syndrome, a severe form of ichthyosis, which is a family of genetic skin disorders associated with thickened scaly skin and characterized by chronic skin inflammation, itchiness, and dehydration.

KRYS Intrinsic Value
113.67 USD
Overvaluation 40%
Intrinsic Value
Price

See Also

What is Krystal Biotech Inc's Revenue?
Revenue
241.5m USD

Based on the financial report for Sep 30, 2024, Krystal Biotech Inc's Revenue amounts to 241.5m USD.

What is Krystal Biotech Inc's Revenue growth rate?
Revenue CAGR 1Y
2 721%

Over the last year, the Revenue growth was 2 721%.

Back to Top